Rituximab, which is currently FDA-approved for the treatment of certain B-cell lymphomas and moderate-to-severe rheumatoid arthritis, demonstrated benefit in the treatment of relapsing-remitting multiple sclerosis (RRMS) in 2 early-phase experimental trials.
Rituximab, which is currently FDA-approved for the treatment of certain B-cell lymphomas and moderate-to-severe rheumatoid arthritis, demonstrated benefit in the treatment of relapsing-remitting multiple sclerosis (RRMS) in 2 early-phase experimental trials. In both studies, the drug was associated with reduced magnetic resonance imaging (MRI) disease activity in RRMS.
The efficacy of rituximab in these trials suggests that B cells play a role in mediating relapses of MS because rituximab is a therapeutic antibody that targets and selectively depletes CD20-positive B cells, said Stephen Hauser, MD, chair of the department of neurology, University of California, San Francisco.
The overall incidence of adverse events was comparable between the 2 groups, except for an excess of infusion-associated adverse events in the rituximab group compared with placebo (78.3% vs 40.0%, respectively).
The second study, a phase 1 study, was an open-label trial of 26 patients who received two 1,000-mg infusions of rituximab administered 2 weeks apart, followed by another course 6 months later. At 48 weeks, the number of new gadolinium-enhancing lesions was reduced by >90% compared with baseline, an effect that was already evident at Week 4, reported Amit Bar-Or, MD, of the Montreal Neurological Institute at McGill University in Montreal, Canada.
A total of 3 relapses were observed among all patients in the study, representing an annualized relapse rate of 0.13 (patients had to have ≥1 relapse in the prior year to be eligible for the study).
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.